{
    "nctId": "NCT00080665",
    "briefTitle": "Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "2.1.1 To determine the safety profile, maximum tolerated dose, and recommended dose for subsequent phase II studies of a combination regimen of daily STI571 with weekly docetaxel on days 1, 8, and 15 in a 28-day cycle.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Stage IIIB, IIIC, or IV disease\n* Measurable or evaluable disease\n* Stable brain metastases allowed provided prior surgery or radiotherapy was completed more than 90 days ago\n* No documented or suspected leptomeningeal disease\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Granulocyte count \u2265 1,500/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 upper limit of normal (ULN)\n* Meets 1 of the following criteria for AST or ALT AND alkaline phosphatase:\n\n  * AST or ALT \u2264 ULN AND alkaline phosphatase \u2264 5 times ULN\n  * AST or ALT \u2264 2.5 times ULN AND alkaline phosphatase \u2264 ULN\n  * AST or ALT \u2264 1.5 times ULN AND alkaline phosphatase \u2264 2.5 times ULN\n* No known acute or chronic liver disease (e.g., chronic active hepatitis or cirrhosis)\n\nRenal\n\n* Creatinine \u2264 1.5 mg/dL\n\nCardiovascular\n\n* No New York Heart Association class III or IV heart disease\n* No congestive heart failure\n* No myocardial infarction within the past 6 months\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for at least 3 months after study participation\n* No other primary malignancy except those malignancies that are clinically insignificant AND do not require active intervention\n* No other concurrent severe and/or life-threatening medical disease\n* No significant history of noncompliance to medical regimens or inability to grant reliable informed consent\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 14 days since prior systemic trastuzumab (Herceptin\u00ae)\n* No concurrent trastuzumab\n* No concurrent biologic therapy for the primary malignancy\n\nChemotherapy\n\n* Prior taxane therapy, including docetaxel, in the adjuvant or metastatic setting allowed\n* At least 21 days since prior systemic chemotherapy (14 days for weekly or oral chemotherapy and 42 days for nitrosoureas or mitomycin)\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* At least 14 days since prior systemic hormonal therapy\n* No concurrent antiestrogen therapy\n* No concurrent routine systemic corticosteroid therapy except as premedication for chemotherapy\n* Concurrent megestrol allowed only as an appetite stimulant\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 14 days since prior radiotherapy\n* No prior radiotherapy to only site of measurable/evaluable disease unless there is new evidence of post-radiotherapy disease progression\n* No concurrent radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n* More than 2 weeks since prior major surgery\n\nOther\n\n* Recovered from all prior therapy\n* At least 14 days since prior daily or weekly systemic investigational treatment\n* No concurrent warfarin for full anticoagulation\n\n  * Concurrent low-dose warfarin (e.g., 1 mg/day) allowed for prophylaxis of central venous access\n* No concurrent treatment with any of the following:\n\n  * Phenobarbital\n  * Phenytoin\n  * Carbamazepine\n  * Barbiturates\n  * Rifampin\n  * Hypericum perforatum (St. John's wort)\n* No other concurrent therapies for the primary malignancy\n* No other concurrent investigational drugs or systemic therapy\n* No concurrent bisphosphonates unless started before study therapy\n* No concurrent grapefruit juice",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}